<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><label>Table 1.</label><caption><title>Clinical and tumor characteristics of patients treated with cTACE and TILA-TACE in the nonrandomized study.</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variables</th><th colspan="2">Patients</th></tr><tr><th valign="top">TILA-TACE</th><th valign="top">cTACE</th></tr></thead><tbody><tr><td>Patient number</td><td>30</td><td>27</td></tr><tr><td>Median age, years</td><td>57 (Range 32&#8211;81)</td><td>54 (Range 37&#8211;81)</td></tr><tr><td>Gender (M/F)</td><td>27/3 (90.0%/10.0%)</td><td>27/0 (100%/0%)</td></tr><tr><td>Aetiology</td><td/><td/></tr><tr><td>&#8195;HBV</td><td>24 (80.0%)</td><td>25&#160;(92.6%)</td></tr><tr><td>&#8195;HCV</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td>&#8195;Non B-non C</td><td>6 (20.0%)</td><td>2&#160;(7.4%)</td></tr><tr><td>Cirrhosis (radiology)</td><td>30 (100%)</td><td>27&#160;(100%)</td></tr><tr><td>Bilirubin, &#956;M</td><td>16.9 &#177; 9.4</td><td>22.5 &#177; 11.6</td></tr><tr><td>Albumin, g/L</td><td>39.0 &#177; 6.9</td><td>37.4 &#177; 5.3</td></tr><tr><td>AST, U/L</td><td>74.9 &#177; 102.3</td><td>83.5 &#177; 54.1</td></tr><tr><td>ALT, U/L</td><td>54.1 &#177; 80.4</td><td>67.3 &#177; 43.5</td></tr><tr><td>AFP, &gt;400&#160;ng/mL</td><td>9 (30.0%)</td><td>15&#160;(55.6%)</td></tr><tr><td>Child-Pugh class, A/B</td><td>27/3 (90.0%/10.0%)</td><td>25/2&#160;(92.6%/7.4%)</td></tr><tr><td>The size of largest tumor (cm)</td><td>9.2 (range 5.0&#8211;13.6)</td><td>10.3 (range 5.0&#8211;14.6)</td></tr><tr><td>&#8195;Tumor &gt;10 cm</td><td>14 (46.7%)</td><td>15&#160;(55.6%)</td></tr><tr><td>&#8195;Tumor 5~10&#160;cm</td><td>16 (53.3%)</td><td>12&#160;(44.4%)</td></tr><tr><td>Multifocal tumors in 1 lobe</td><td>8 (26.7%)</td><td>12&#160;(44.4%)</td></tr><tr><td>Multifocal tumors in 2 lobes</td><td>8 (26.7%)</td><td>12&#160;(44.4%)</td></tr><tr><td>BCLC stage</td><td/><td/></tr><tr><td>&#8195;B</td><td>19 (63.3%)</td><td>18&#160;(66.7%)</td></tr><tr><td>&#8195;C</td><td>11 (36.7%)</td><td>9&#160;(33.3%)</td></tr><tr><td>Macrovascular invasion</td><td>5 (16.7%)</td><td>4&#160;(14.8%)</td></tr><tr><td>&#8195;The right branch of portal vein</td><td>4 (13.3%)</td><td>2&#160;(7.4%)</td></tr><tr><td>&#8195;Hepatic vein</td><td>&#8211;</td><td>1&#160;(3.7%)</td></tr><tr><td>&#8195;The right branch of portal + hepatic vein</td><td>1 (3.3%)</td><td>1&#160;(3.7%)</td></tr><tr><td>Extra-hepatic metastasis</td><td>8 (26.7%)</td><td>8&#160;(29.6%)</td></tr><tr><td>&#8195;Lung</td><td>1 (3.3%)</td><td>6&#160;(22.2%)</td></tr><tr><td>&#8195;Lung + bone</td><td>1 (3.3%)</td><td>0 (0%)</td></tr><tr><td>&#8195;Soft tissue</td><td>&#8211;</td><td>0 (0%)</td></tr><tr><td>&#8195;Lymph nodes</td><td>5 (12.2%)</td><td>0 (0%)</td></tr><tr><td>&#8195;Bone</td><td>1 (2.0%)</td><td>1&#160;(3.7%)</td></tr><tr><td>&#8195;Bone+lymph node</td><td>&#8211;</td><td>1&#160;(3.7%)</td></tr></tbody></table><table-wrap-foot><fn><p>HBV, hepatitis B virius;</p><p>HCV, hepatitis C virius;</p></fn><fn><p>AST, Aspartate transaminase;</p><p>ALT, Alanine aminotransferase;</p></fn><fn><p>AFP, alpha-feto-protein.</p></fn></table-wrap-foot></table-wrap>